ACCESSIBILITY

24/7

Headlines

21:14

Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program

19:40

Greece approves $750M rocket deal with Elbit amid negotiations for $3.5B Israeli air-defense systems

19:09

Intel VP: “We’re just not going to accept subpar products”

10:39

Intel’s decision to keep NEX signals stability for Israel’s 350 networking staff

Buzz

Most popular

Daily

Weekly

“Other countries have air-defense systems, but Israel’s are better”: Arrow 3 lands in Germany as Israel pursues new mega deals

Nice puts Actimize up for sale at a $1.5-2 billion price tag

Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program

Zafran raises $60 million and doubles valuation as it chooses independence over takeover offers

Israeli drone startup Heven hits $1 billion valuation in $100 million round led by IonQ

More news

Kåre Schultz

9 stories about Kåre Schultz

Teva Announces Restructuring, Ousts Second in Command

27.11.17|Golan Hazani

The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately

Israeli Parliamentarians to Push Against Teva Layoffs in the Country

26.11.17|Dror Reich and Maayan Manela

Shelly Yachimovich, a member of the Israeli parliament representing the Israeli Labor Party, said she intends to call an emergency hearing of the Israeli parliament’s state control committee on the issue. The planned layoffs are a result of the company’s management failures, she added

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani

Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden

Generic Dependence Threatens Teva’s Ability to Haul Debt Load

05.11.17|Dror Reich and Lilach Baumer

Teva’s stock price dropped 18.7% last week after the company lowered its annual forecasts. On Friday, S&P changed the company’s outlook to negative

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich

Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer

The generic drugmaker shed 67% of its market price over the last 12 months

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17|Golan Hazani

Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman

Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld

The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated